CNMD Stock Analysis: CONMED | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.530m USD | 12M Return: -5.5% | US2074101013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.5M
EPS Trend: 93.2%
Qual. Beats: 3
Rev. Trend: 94.9%
Qual. Beats: 5
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CONMED Corporation (NYSE: CNMD) is a U.S.-based medical technology company that develops, manufactures, and sells surgical devices and equipment across three main product categories: orthopedic surgery, general surgery, and endoscopic technologies. Its orthopedic offerings include soft tissue fixation systems like BioBrace and the Y-Knot suture anchor family, along with powered resection instruments and fluid management systems used in minimally invasive sports medicine procedures, while its Hall surgical brand provides battery-powered bone power tools for orthopedic, spinal, and cardiothoracic applications. The general surgery portfolio spans insufflation systems (AirSeal), smoke removal devices (Buffalo Filter), endomechanical products, and electrosurgical generators and accessories, and the endoscopic segment supplies devices for gastroenterology procedures as well as electrodes and defibrillation pads for patient monitoring. CONMED sells its products directly to hospitals and ambulatory surgery centers and through medical specialty distributors, and the company is headquartered in Largo, Florida.
The medical device industry is characterized by long product development cycles, regulatory approval requirements from bodies such as the U.S. Food and Drug Administration, and demand driven by surgical procedure volumes in aging populations. CONMEDs broad portfolio across orthopedic, general surgery, and endoscopy gives it exposure to multiple procedure types while concentrating on the minimally invasive surgery segment, which has been a long-standing growth area in the health care equipment sub-industry.
- AirSeal insufflation system drives General Surgery segment growth
- Hospital capital spending slowdown pressures procedural device demand
- Competition from Stryker and J&J challenges orthopedic market share
| Net Income: 56.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.52 > 1.0 |
| NWC/Revenue: 16.05% < 20% (prev 27.39%; Δ -11.34% < -1%) |
| CFO/TA 0.07 > 3% & CFO 150.6m > Net Income 56.5m |
| Net Debt (819.7m) to EBITDA (180.0m): 4.55 < 3 |
| Current Ratio: 1.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.1m) vs 12m ago -3.02% < -2% |
| Gross Margin: 54.80% > 18% (prev 54.77%; Δ 0.03% > 0.5%) |
| Asset Turnover: 59.31% > 50% (prev 56.91%; Δ 2.40% > 0%) |
| Interest Coverage Ratio: 3.78 > 6 (EBIT TTM 113.1m / Interest Expense TTM 29.9m) |
| A: 0.10 (Total Current Assets 675.7m - Total Current Liabilities 455.4m) / Total Assets 2.30b |
| B: 0.27 (Retained Earnings 625.7m / Total Assets 2.30b) |
| C: 0.05 (EBIT TTM 113.1m / Avg Total Assets 2.31b) |
| D: 0.83 (Book Value of Equity 1.04b / Total Liabilities 1.26b) |
| Altman-Z'' = 2.71 = A |
| DSRI: 0.99 (Receivables 239.8m/234.1m, Revenue 1.37b/1.33b) |
| GMI: 1.00 (GM 54.77% / 54.80%) |
| AQI: 0.99 (AQ_t 0.66 / AQ_t-1 0.67) |
| SGI: 1.04 (Revenue 1.37b / 1.33b) |
| TATA: -0.04 (NI 56.5m - CFO 150.6m) / TA 2.30b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of August 26, 2026, the stock is trading at USD 51.13 with a total of 296,641 shares traded. Over the past week, the price has changed by +3.80%, over one month by +17.51%, over three months by +41.79% and over the past year by -5.45%.
Current recommended Stop Loss: 48.50 (which is 5.1% or 1.3 ATR below the current price).
CONMED has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CNMD.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45.5 | -11% |
P/E Trailing = 27.6054
P/E Forward = 27.1739
P/S = 1.1152
P/B = 1.4688
P/EG = 1.8437
Revenue TTM = 1.37b USD
EBIT TTM = 113.1m USD
EBITDA TTM = 180.0m USD
Long Term Debt = 657.0m USD (from longTermDebt, last quarter)
Short Term Debt = 177.2m USD (from shortTermDebt, last quarter)
Debt = 857.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 22.8m
Net Debt = 819.7m USD (calculated: Debt 857.1m - CCE 37.3m)
Enterprise Value = 2.35b USD (1.53b + Debt 857.1m - CCE 37.3m)
Interest Coverage Ratio = 3.78 (Ebit TTM 113.1m / Interest Expense TTM 29.9m)
EV/FCF = 17.47x (Enterprise Value 2.35b / FCF TTM 134.5m)
FCF Yield = 5.72% (FCF TTM 134.5m / Enterprise Value 2.35b)
FCF Margin = 9.80% (FCF TTM 134.5m / Revenue TTM 1.37b)
Net Margin = 4.12% (Net Income TTM 56.5m / Revenue TTM 1.37b)
Gross Margin = 54.80% ((Revenue TTM 1.37b - Cost of Revenue TTM 620.4m) / Revenue TTM)
Gross Margin QoQ = 57.49% (prev 57.86%)
Tobins Q-Ratio = 1.02 (Enterprise Value 2.35b / Total Assets 2.30b)
Interest Expense / Debt = 3.49% (Interest Expense 29.9m / Debt 857.1m)
Taxrate = 32.12% (26.7m / 83.2m)
NOPAT = 76.8m (EBIT 113.1m * (1 - 32.12%))
Current Ratio = 1.48 (Total Current Assets 675.7m / Total Current Liabilities 455.4m)
Debt / Equity = 0.82 (Debt 857.1m / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 4.55 (Net Debt 819.7m / EBITDA 180.0m)
Debt / FCF = 6.10 (Net Debt 819.7m / FCF TTM 134.5m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.44% (Net Income 56.5m / Total Assets 2.30b)
RoE = 5.51% (Net Income TTM 56.5m / Total Stockholder Equity 1.03b)
RoCE = 6.73% (EBIT 113.1m / Capital Employed (Equity 1.03b + L.T.Debt 657.0m))
RoIC = 3.87% (NOPAT 76.8m / Invested Capital 1.98b)
WACC = 7.19% (E(1.53b)/V(2.39b) * Re(9.89%) + D(857.1m)/V(2.39b) * Rd(3.49%) * (1-Tc(0.32)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.85 | Cagr: -1.66%
[DCF] Terminal Value 74.08% ; FCFF base≈140.0m ; Y1≈129.6m ; Y5≈116.7m
[DCF] Fair Price = 34.33 (EV 1.85b - Net Debt 819.7m = Equity 1.03b / Shares 30.0m; r=8.35% [WACC [floored]]; 5y FCF grow -9.29% → 2.50% )
EPS Correlation: 93.17 | EPS CAGR: 17.52% | SUE: 4.0 | # QB: 3
Revenue Correlation: 94.92 | Revenue CAGR: 5.18% | SUE: 1.99 | # QB: 5
EPS current Quarter (2026-09-30): EPS=1.00 | Chg30d=-3.14% | Revisions=-50% | Analysts=7
EPS current Year (2026-12-31): EPS=4.54 | Chg30d=+3.99% | Revisions=+62% | GrowthEPS=-1.2% | GrowthRev=-0.6%
EPS next Year (2027-12-31): EPS=4.78 | Chg30d=+0.32% | Revisions=+12% | GrowthEPS=+5.4% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +19% (up=8, down=5)